Nonalcoholic Steatohepatitis

Sheth, Sunil G.

doi:10.7326/0003-4819-126-2-199701150-00008

Cited by 510 publications

(373 citation statements)

References 0 publications

Supporting

Mentioning

306

Contrasting

Unclassified

Order By: Relevance

“…1 Obesity is the commonest association with NAFLD; 69-100% of patients with NASH are obese. 39 In 1515 patients with morbid obesity, only 12% of liver biopsies were found to be normal; 3% had cirrhosis and 80% fatty liver. 40 In a series of 551 liver biopsies performed on patients with severe obesity undergoing bariatric surgery, 86% had steatosis, 24% steatohepatitis and 2% cirrhosis.…”

Section: Hypertension Metabolic Syndrome and Fatty Livermentioning

confidence: 99%

Hypertension and fatty liver: guilty by association?

Brookes

Cooper

2007

J Hum Hypertens

View full text Add to dashboard Cite

Section: Hypertension Metabolic Syndrome and Fatty Livermentioning

confidence: 99%

Hypertension and fatty liver: guilty by association?

Brookes

Cooper

2007

J Hum Hypertens

View full text Add to dashboard Cite

“…Approximately 50% of patients with steatohepatitis develop fibrosis, 15% develop cirrhosis, and 3% develop liver failure (4). If the prevalence of type 2 diabetes will grow as predicted in the next 50 years, NAFLD will likely become a prominent public health issue and an important cause of cirrhosis and liver failure.…”

mentioning

confidence: 99%

Effect of insulin–metformin combination on hepatic steatosis in patients with type 2 diabetes

Lingvay¹,

Raskin²,

Szczepaniak³

2007

Journal of Diabetes and its Complications

View full text Add to dashboard Cite

Objective-Hepatic steatosis occurs in up to 78% of patients with type 2 diabetes. Studies evaluating the effect of metformin on hepatic steatosis are conflicting. Insulin is believed to be detrimental due to its lipogenic effect. Since insulin and metformin combination is commonly used for the treatment diabetes, it is important to assess the effect of this combined therapy on hepatic steatosis. We evaluated the change in hepatic steatosis following initiation of insulin and metformin in patients with type 2 diabetes.Methods-Newly-diagnosed, treatment-naïve patients with type 2 diabetes had their hepatic triglyceride (TG) content measured by magnetic resonance spectroscopy at baseline and after 3 months of treatment with BiAsp 30 insulin in combination with metformin. Insulin was administered twice daily and titrated to achieve normal capillary blood glucose levels. Metformin was titrated during the first month from 500 mg daily to 1000 mg twice-daily.Results-The average hepatic TG content in the 19 subjects enrolled was 11.83%±7.61% (range 0.93% to 23.16%)] and correlated with BMI (r=0.567). Three months of treatment reduced hepatic steatosis by 45%, with 75% of the study subjects achieving a normal level. The change in hepatic TG content was partially explained by the change in HbA1c (p=0.006) and change in cholesterol level (p=0.003).Conclusions-The combined treatment with insulin and metformin reduced significantly hepatic steatosis in patients with newly-diagnosed type 2 diabetes. Keywords type 2 diabetes; hepatic steatosis; insulin treatment; metformin Non-alcoholic fatty liver disease (NAFLD) is characterized by fatty infiltration of the liver. This diagnosis represents a disease spectrum from simple steatosis to steatohepatitis. The prevalence of NAFLD has risen in the last decade parallel with the obesity and type 2 diabetes epidemics. (1). Previous studies suggest that one-third of the population has NAFLD (2). The prevalence of NAFLD in patients with type 2 diabetes is even higher. In the Dallas Heart Study,

show abstract

“…NAFLD enhance the progression of fibrosis, liver cirrhosis, and liver failure [2]. Fat accumulation in the liver cell is characteristic feature of development of NAFLD [3].…”

Section: Introductionmentioning

confidence: 99%

Study of serum ferritin, serum uric acid and plasma malondialdehyde (MDA) levels in non-alcoholic fatty liver disease

Varma¹,

Makwane²,

Kare³

et al. 2016

Int J of Biomed & Adv Res

View full text Add to dashboard Cite

Background: Non-alcoholic fatty liver disease (NAFLD) is one of most important cause of fatty liver that may lead to endstage liver disease. Various studies have reported that serum ferritin, serum uric acid and plasma malondialdehyde (MDA) levels are related to the development of NAFLD. Diabetes and obesity are the major risk factors which are associated with NAFLD. The aim of this study was estimation of serum ferritin, serum uric acid and plasma MDA levels in NAFLD patients with diabetes and with obesity. Materials and Methods:In the present study, total (n = 230) subjects were recruited for the study and divided in three groups. Group I; (n = 79) diagnosed cases of non-alcoholic fatty liver disease with diabetes, group II; (n = 71) diagnosed cases of nonalcoholic fatty liver disease with obesity patients and group III included (n = 80) healthy control subjects. Serum ferritin was measured by ELISA method. Estimation of serum uric acid was done by uricase peroxidase colorimetric method. Plasma MDA was estimated by spectrophotometric method. Results: The present study shown that serum ferritin, serum uric acid and plasma MDA levels were significantly increased (p<0.001) in NAFLD with diabetes mellitus patients (333.42±82.93, 14.29±1.87, 7.75±3.35, respectively) as compared with healthy controls (126.30±72.12, 5.19±1.72, 2.79±0.52, respectively), and also significantly increased (p < 0.001) in NAFLD with obesity patients (300.87±85.80, 12.08±2.81, 7.43±3.05, respectively) when they compared with healthy controls (126.30±72.12, 5.19±1.72, 2.79±0.52, respectively). Conclusion: Serum ferritin, serum uric acid and plasma MDA are associated with the increased risk for non-alcoholic fatty liver disease.

show abstract

Nonalcoholic Steatohepatitis

Cited by 510 publications

References 0 publications

Hypertension and fatty liver: guilty by association?

Hypertension and fatty liver: guilty by association?

Effect of insulin–metformin combination on hepatic steatosis in patients with type 2 diabetes

Study of serum ferritin, serum uric acid and plasma malondialdehyde (MDA) levels in non-alcoholic fatty liver disease

Contact Info

Product

Resources

About